Modality
Cell Therapy
MOA
Menini
Target
CD123
Pathway
PD-1/PD-L1
MSGBM
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Oct 2026
Phase 1Current
NCT06935240
889 pts·MS
2019-12→2026-10·Active
889 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-217mo awayPh2 Data· MS
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2026-10-21 · 7mo away
MS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06935240 | Phase 1/2 | MS | Active | 889 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zorizumab | Beam | Approved | CD123 | |
| Adagralucimab | Caribou Bio | NDA/BLA | CD123 | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |